These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344 [TBL] [Abstract][Full Text] [Related]
7. Mutational profiling of colorectal cancers with microsatellite instability. Lin EI; Tseng LH; Gocke CD; Reil S; Le DT; Azad NS; Eshleman JR Oncotarget; 2015 Dec; 6(39):42334-44. PubMed ID: 26517354 [TBL] [Abstract][Full Text] [Related]
8. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237 [TBL] [Abstract][Full Text] [Related]
9. KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. Rechsteiner M; von Teichman A; Rüschoff JH; Fankhauser N; Pestalozzi B; Schraml P; Weber A; Wild P; Zimmermann D; Moch H J Mol Diagn; 2013 May; 15(3):299-311. PubMed ID: 23531339 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183 [TBL] [Abstract][Full Text] [Related]
12. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors. Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867 [TBL] [Abstract][Full Text] [Related]
13. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. Li W; Qiu T; Guo L; Ying J Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013 [TBL] [Abstract][Full Text] [Related]
14. Mutational Heterogeneity in Gausachs M; Borras E; Chang K; Gonzalez S; Azuara D; Delgado Amador A; Lopez-Doriga A; San Lucas FA; Sanjuan X; Paules MJ; Taggart MW; Davies GE; Ehli EA; Fowler J; Moreno V; Pineda M; You YN; Lynch PM; Lazaro C; Navin NE; Scheet PA; Hawk ET; Capella G; Vilar E Clin Cancer Res; 2017 Oct; 23(19):5936-5947. PubMed ID: 28645942 [No Abstract] [Full Text] [Related]
15. Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer. Büttner J; Jöhrens K; Klauschen F; Hummel M; Lenze D; Saeger W; Lehmann A Exp Mol Pathol; 2018 Feb; 104(1):76-81. PubMed ID: 29337243 [TBL] [Abstract][Full Text] [Related]
16. Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA. Chang LC; Chiu HM; Shun CT; Liang JT; Lin JT; Chen CC; Lee YC; Wu MS BMC Gastroenterol; 2014 Dec; 14():221. PubMed ID: 25551625 [TBL] [Abstract][Full Text] [Related]
17. Molecular alterations in colitis-associated colorectal neoplasia: study from a low prevalence area using magnifying chromo colonoscopy. Shivakumar BM; Kumar BL; Bhat G; Suvarna D; Rao L; Pai CG; Satyamoorthy K J Crohns Colitis; 2012 Jul; 6(6):647-54. PubMed ID: 22398042 [TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. Jesinghaus M; Pfarr N; Kloor M; Endris V; Tavernar L; Muckenhuber A; von Knebel Doeberitz M; Penzel R; Weichert W; Stenzinger A Genes Chromosomes Cancer; 2016 Mar; 55(3):268-77. PubMed ID: 26650777 [TBL] [Abstract][Full Text] [Related]
19. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750 [TBL] [Abstract][Full Text] [Related]
20. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations. Holck S; Bonde J; Pedersen H; Petersen AA; Chaube A; Nielsen HJ; Larsson LI Hum Pathol; 2016 Aug; 54():37-46. PubMed ID: 27036313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]